Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291922 | 1.00 | ADORA2A (0.56) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL291921 | 1.00 | ADORA2A (0.56) | ADORA2AADORA3ADORA2BADORA1 | |
| Trifluoroacetic Acid SCHEMBL241434 | 0.96 | ADORA2A (0.53) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL242476 | 0.94 | ADORA2A (0.49) | ADORA2AADORA3ADORA1 | |
| SCHEMBL242478 | 0.94 | ADORA2A (0.49) | ADORA2AADORA3ADORA1 | |
| SCHEMBL242477 | 0.94 | ADORA2A (0.49) | ADORA2AADORA3ADORA1 | |
| SCHEMBL10156281 | 0.94 | ADORA2A (0.61) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL10195035 | 0.94 | ADORA2A (0.61) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL10155736 | 0.94 | ADORA2A (0.61) | ADORA2AADORA3ADORA2BADORA1 | |
| Trifluoroacetic Acid SCHEMBL4129316 | 0.94 | ADORA2A (0.51) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-2018388-B9 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-2018388-B1 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2011-03-16 | — | — | EP | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | ADORA2A 1137/4885ADORA3 1044/4885ADORA2B 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.